Free Trial!
Today’s Best Stocks To Trade! Click Here
Visit http://www.otcpicks.com to register for our Daily Market Mover's Digest Newsletter and Email Stock Watch Alerts.
COPPER KING MINING CORPORATION (OTC: CPRK)
Detailed Quote: www.otcpicks.com/quotes/CPRK.php
Company Profile: www.otcpicks.com/copper-king-mining/copper-king-mining.htm
Copper King Mining Corporation currently owns approximately 1200 acres in the Drum Mountains of Utah, which are patent deeded mining claims which contain gold, silver and copper. The company recently added to its holdings by filing six more claims on land which was inside their holdings, but not patent deeded. Contiguous to that acreage is approximately 1100 acres of claims filed by Western Utah Copper Company. As the companies explored the concept of a joint venture on the Drum Mountain properties, it was decided that a very viable consideration was to join the total assets of both companies.
CPRK News:
July 15 - Copper King Mining Corporation Announces Construction Updates
Copper King Mining Corporation (OTC: CPRK), an ore mining, processing, and Exploration company located in Southern Utah, today offered updates regarding its Floatation Mill's construction near Milford, Utah.
Copper King announced today that it awarded the bid to construct the substation that will supply power to the Copper King concentrator as part of its Floatation Mill construction to AF Electric. AF intends to begin work next week. Construction of the Master Control Center building has commenced and is targeted to be completed in 3 weeks. Placement of electric cable trays and heavy conduit inside the concentrator, which will provide power to the ball mills and cyclone deck, will begin this week also.
July 15 - Copper King Mining Corporation Offers Corporate Updates
Copper King Mining Corporation (OTC: CPRK), an ore mining, processing, and exploration company located in Southern Utah, provided updates concerning prior officers of Copper King Mining Corporation.
In response to shareholder inquiry, Copper King announced that neither Daryl nor Sandra Nether are Copper King officers, directors or insiders and are not involved in the company's operations. Daryl and Sandra Nethers are Copper King shareholders. The company is in the process of updating its information on Pink Sheets.com in order to remove any incorrect, outdated, inaccurate or derogatory data. Pink Sheets.com is not a governmental regulatory entity but rather a private company that provides a forum to lodge information about companies listed on the Pink Sheet Exchange to the public.
LANTIS LASER INCORPORATED (OTC: LLSR)
Detailed Quote: http://www.otcpicks.com/quotes/LLSR.php
Company Profile: http://www.otcpicks.com/lantis-laser/lantis-laser-2.htm
Lantis Laser was formed to commercialize the application of novel technologies in the dental industry. The criteria for selected products include competitive edge, exclusivity and large market potential. Lantis is currently in Phase 2 development, moving through beta systems, product development and application for FDA clearance and plans to launch the OCT Dental Imaging System in the first quarter of 2009. Lantis has exclusive rights to the application of OCT technology in the field of dentistry under its license Agreements with Lawrence Livermore National Laboratory (exclusive); LightLab Imaging (non-exclusive) and AXSUN (exclusive). To find out more about Lantis Laser, visit www.lantislaser.com.
LLSR News:
July 15 - Lantis' OCT Dental Imaging System Featured in Report on Light-Based Diagnostic Modalities for Early Decay
Lantis Laser Inc. (OTC: LLSR | Quote | Chart | News | PowerRating) (www.lantislaser.com) issued a statement drawing attention to a recent significant report on a leading professional dental website, www.DrBicuspid.com, highlighting the status of light-based diagnostic modalities for the early detection of decay.
Early detection of decay is an important part in the practice of minimally invasive dentistry and the "medical model" of finding disease early and treating it early with topical or chemical means to avoid surgical intervention.
Lantis' OCT Dental System is addressed in Part III.
The report was published on the Internet in three parts, with the last, Part III, titled:
"Beyond x-rays: Part III - OCT brings early decay to light" www.drbicuspid.com/index.aspx?sec=sup&sub=img&pag=dis&ItemID=300735&wf=3 4
Links to Part I and Part II, which discuss currently available diagnostic products, are accessible at the end of Part III.
Lantis' OCT Dental Imaging System is based on novel, light-based bio-medical imaging technology, Optical Coherence Tomography (OCT), that enables the dentist to do diagnostic imaging, chairside and in real-time. Images can be captured at a resolution of up to 10 times that of x-ray, enabling early detection of decay and detailed examination of microstructural defects. As the power source is light-based, unlike x-ray there is no harmful radiation.
BROWNSTONE RESOURCES INCORPORATED (OTC: BWNR | Quote | Chart | News | PowerRating) "Up 21.43% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/BWNR.php
Brownstone is a gold exploration company focused on creating value for shareholders by exploring and developing high-grade gold mining properties. Details of Brownstones projects are available on the Company's website at www.brownstoneresources.com.
BWNR News:
July 15 - Brownstone Completes Earn in of 'LS Grande' Gold/Silver/Copper Property, Comments on Approval of 'Phase One' Plan
Brownstone Resources Inc. (OTC: BWNR | Quote | Chart | News | PowerRating) announced that the company has completed their option payments to date as required for the earn in portion of the "LS Grande" gold/silver/copper property, located in NE Arizona.
Additionally, Brownstone has received the "Phase One" development plan for the LS Grande, and is in the process of reviewing the plan for approval. Management anticipates final approval of the plan within the next few days.
"We are really excited about the prospects of the LS Grande property, the potential of the project and the effectiveness of the plan to deliver the results we are after. We have completed some limited ground geophysics, and collected surface samples for assaying... now we are going to proceed with putting a few holes down and, in due course, move forward with the completion of phase one," said Ken Lamb, Brownstone Resources Inc.
Phase One is proposed to include a limited drill program to further test the zone at depth, along with core sampling and assaying, followed by additional prospecting, claim staking, and more surface sampling.
Brownstone will announce a start date for commencement of work once the plan has been approved.
ACCENTIA BIOPHARMACEUTICALS INCORPORATED (NASDAQ: ABPI | Quote | Chart | News | PowerRating) "Up 12.93% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/ABPI.php
Immunosyn Corporation, a development stage company, engages in the marketing, distribution, and sale of a biopharmaceutical drug product, SF-1019. The company owns license rights from Argyll Biotechnologies, LLC to offer SF-1019, an experimental extract from caprine serum containing various lipopeptide molecules. SF-1019 is used for the treatment of various diseases and pathological conditions, including Chronic Inflammatory Demyelinating Polyneuropathy, Diabetic Neuropathy, and diabetic ulcers. The company was founded in 2006 and is headquartered in La Jolla, California. Immunosyn Corporation is a subsidiary of Argyll Biotechnologies, LLC.
ABPI News:
July 17 - Biovest Reports Results for Patients Treated with Anti-Cancer Vaccine: BiovaxID Demonstrates Clinically and Statistically Significant Improvement of Disease-Free Survival in Non-Hodgkin's Lymphoma in Pivotal Phase 3 Clinical Trial
* Overall median disease-free-survival increased by more than one year (p-value = 0.047)
* 100% improvement in disease-free-survival at three years (p-value = 0.024)
* Potential to be first ever anti-cancer vaccine approved in U.S. and/or Europe
Biovest International, Inc. (OTCBB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI), announced clinically and statistically significant unblinded data from its randomized controlled pivotal Phase 3 Fast-Tracked clinical trial of BiovaxID (personalized anti-idiotype vaccine) for the treatment of indolent follicular non-Hodgkin's lymphoma (NHL), an often fatal blood cancer. Originally developed and advanced into human clinical trials by the National Cancer Institute (NCI), BiovaxID is designed to recruit the immune system to recognize and destroy only cancerous B-cells. Based on this study's highly encouraging clinical evidence reporting on vaccinated patients to date, including efficacy and safety, Biovest intends to move forward with plans to seek accelerated and/or conditional regulatory approvals in the U.S. and European Union, respectively.
Summary Results
Biovest reported on two clinically relevant data points: 1) Overall median disease-free survival data as measured up to 80 months; and 2) Disease-free survival data on these same patients as measured at three years. All analyses performed were predetermined prior to unblinding and consistent with the Statistical Analysis Plan that was submitted and accepted by the FDA and the data review performed by the independent Data Monitoring Committee (DMC), which is vested with the responsibility for monitoring the safety and efficacy of the BiovaxID trial.
First, for vaccinated patients followed up to 80 months, the overall results showed that BiovaxID improved median disease-free-survival by more than one year with the control arm showing a median time to relapse from first vaccination of 21.2 months, as compared to the BiovaxID arm which had a median time to relapse of 33.8 months. This statistically significant difference (p-value = 0.047) represents an increase of approximately 60% in the duration of complete remission since first vaccination. Disease-free survival (how long patients remain in cancer-free remission) is the primary endpoint of the study.
Second, for these same patients measured at 36 months from vaccination, BiovaxID improved median disease-free-survival by approximately 100% - a statistically significant improvement as compared to the control group (p-value = 0.024).
Biovest intends to seek accelerated and/or conditional approvals immediately in the U.S. and Europe, respectively, based on the current unblinded data and plans to supplement the clinical analysis with additional follow-up data through August 29, 2008, as per the recommendation of the DMC.
According to the Leukemia & Lymphoma Society, non-Hodgkin's lymphoma is the 5th leading cause of new cancer cases in the U.S., with an estimated 63,190 new cases of NHL to be diagnosed in 2008, with approximately 18,660 deaths expected to be attributed to the disease. In Europe, NHL is the 6th most common form of cancer with approximately 50,000 new cases diagnosed each year in the European Union alone.
ABOUT BIOVAXID
BiovaxID is a personalized, patient-specific therapeutic vaccine designed to stimulate the patient's own immune system to recognize and destroy cancerous B-cells that may remain in the body or may arise after the patient has been treated with chemotherapy. Unlike many other approaches to treating non-Hodgkin's lymphoma, BiovaxID is designed to kill only cancerous B-cells, with the initial indication of follicular Non-Hodgkin's lymphoma. Additionally, we anticipate that BiovaxID could potentially be used to treat other types of B-cell cancers, such as Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma.
ABOUT BIOVEST INTERNATIONAL, INC.
Biovest International, Inc. is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., (NASDAQ: ABPI | Quote | Chart | News | PowerRating) with its remaining shares publicly traded. Biovest has a foundation in the manufacture of biologics for research and clinical trials. In addition, Biovest develops, manufactures and markets patented cell culture systems, including the innovative AutovaxID, which is being marketed as an automated vaccine manufacturing instrument and for production of cell-based materials and therapeutics. Biovest is currently completing a pivotal Phase 3 clinical trial for BiovaxID , which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA and Orphan Drug status by the EMEA.
RIT TECHNOLOGIES LIMITED (NASDAQ: RITT | Quote | Chart | News | PowerRating) "Up 19.05% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/RITT.php
RiT Technologies, Ltd. develops intelligent physical layer management solutions. Its products include PatchView, an intelligent infrastructure management solution that provides real-time connectivity information to the data network's connectivity infrastructure; SMART Cabling System, a structured cabling system for commercial buildings; and PairView, an outside plant management and qualification system, which enables telephone companies to identify, record, and test the connectivity routing of local loop pairs and updating the telephone companies' database. The company also offers PairQ, a digital subscriber line (DSL) mass loop qualification product line that qualifies existing copper infrastructure for the provision of DSL services; and PairView Pro, a local loop mass verification system, which identifies and maps various digital services carried on a line. RiT Technologies markets its solutions primarily through distributors, strategic alliance partners, value-added resellers, system integrators, original equipment manufacturers, and installers. The company serves customers in the United States, Europe, Israel, Latin America, the Asia Pacific, and Africa. It has strategic partnerships with Panduit Corporation, LS Cables, Connectix, Brand-Rex, Belden/CDT, and ADC for the sale of its PatchView system. The company was founded in 1989 and is headquartered in Tel Aviv, Israel.
RITT News:
July 17 - RiT Receives Orders Totaling Several Million Dollars From Two Major Carriers
Kazakhstan's National Carrier Chooses RiT/3M as Part of Nationwide Project to Modernize and Digitalize its Local Loop
RiT Delivers Repeat Order to Leading East European Telco RiT Technologies (NASDAQ: RITT), the world-leading provider of intelligent infrastructure solutions, today announced that it has received orders totaling several million dollars from its distributor 3M (NYSE: MMM) on behalf of JSC Kazakhtelecom, Kazakhstan's national carrier, and an Eastern European national telecommunications service provider.
The Kazakhtelecom order was made after the successful completion of an extensive competitive tender process, during which the Company and 3M jointly proposed an advanced nationwide telecommunications infrastructure solution. Kazakhtelecom will be deploying RiT's state-of-the-art PairView#(TM) (PairView Sharp) local loop verification and operations support solution in conjunction with its PairQ(TM) xDSL mass-qualification solution.
As part of the deployment process, the Company will be localizing its Carrier software and documentation to the Russian language, an effort that will enhance RiT's ability to market in the Commonwealth of Independent States (CIS).
Commenting on the news Mr. A. Popov, Technical director of Almatytelecom, the largest branch of JSC Kazakhtelecom, said, "RiT manufactures unique, first class products which will allow us to considerably reduce the quantity of personnel required to carry out our ongoing inventory accounting and management initiatives. The equipment will allow us to automate the preparation and execution of many processes, enabling us to accelerate the completion of our large-scale, national infrastructure and network modernization projects."
The other leading East European telecommunications service provider has been using RiT's PairView Pro systems for the past two years, and is now adding PairView# as part of its strategy for rolling out Next Generation 'Triple Play' services.
Initial deliveries of the equipment were completed during the second quarter, while the majority of the equipment is scheduled to be delivered during the third quarter.
Mr. F. Huber, MD of 3M East AG, commented, "Our cooperation with RiT has enabled us to offer an extremely compelling solution to both Kazakhtelecom and another leading carrier, both of which are leading players in the telecommunications revolution currently underway throughout the CIS. By combining RiT's advanced mapping and monitoring solutions with our product platform, we are able to bring a new level of visibility to the last-mile network, giving operators the tools they need to achieve efficiency in physical plant planning and deployment."
"We are very pleased to report these important sales, both of which demonstrate the success of our sales and support organizations in the CIS and Eastern Europe," added Mr. Avi Kovarsky, RiT's President & CEO. "Our success reflects the strength of our cooperation with 3M, which has enabled us to propose a uniquely comprehensive, field-proven solution. Looking forward, given our expanded regional references and newly localized products, we feel particularly well positioned to continue building our business throughout these dynamic regions."
ABOUT 3M COMPANY
A recognized leader in research and development, 3M produces thousands of innovative products for dozens of diverse markets. 3M's core strength is applying its more than 40 distinct technology platforms - often in combination - to a wide array of customer needs. With $24 billion in sales, 3M employs 75,000 people worldwide and has operations in more than 60 countries. For more information, visit www.3M.com.
ABOUT JSC KAZAKHTELECOM
JSC Kazakhtelecom is the national telecommunication operator of Kazakhstan and one of the fastest developing telecommunication companies in the Former Soviet Union region. The company currently serves approximately three million subscribers, and is engaged in an extensive project to expand network coverage while modernizing and digitalizing its infrastructure. As a result of its accomplishments, the company was named "Best Telecommunications Company in Central Asia" by Euromoney Magazine in 2006.
ABOUT OTCPICKS.COM
OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks.com has been compensated two hundred thousand restricted 144 shares from a third party for LLSR advertising and promotional services. OTCPicks.com has been compensated sixteen thousand five hundred dollars by a third party for CPRK advertising and promotional services. For a complete list of disclosures go to http://www.otcpicks.com/disclosure-details.htm. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.
The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.
Third Party Web Sites and Information:
OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.
CONTACT: Brian Dean, Publisher, OTCPicks.com Tel: +1 972 546 3740 e-mail: publisher@otcpicks.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
